BIOLOG-ID
Biolog-id, a global service provider of connected healthcare solutions, and Fujicom, a national distributor of high-quality medical-hospital products and services, get into a partnership to offer Biolog Transfusion Solution on the Brazilian market.
With more than 40 years of experience in the healthcare sector, Fujicom is a leading supplier in the market by providing high technology medical equipment. Throughout Brazil, the company provides more than 500 customers such as blood centers, public and private blood banks, hospitals and clinics with breakthrough and innovative products.
Flexible and reliable, Biolog Transfusion Solution combines software, equipment and RFID tags offering a comprehensive solution for blood components traceability, from the collection to the hospital blood banks. Divided into several modules (Processing, Inventory and Transport) addressing each application area of the transfusion supply chain, this solution optimizes the management of the lifesaving medical resources while enhancing operational efficiency.
“Due to its core business and its well-recognized experience, Fujicom is without a doubt a key player on the Brazilian transfusion market. We are very pleased to cooperate with them.” explains Philippe Jacquet, Executive Director of Sales EMEA/LATAM at biolog-id. “Several opportunities have already been identified and we are confident that during the coming months, Fujicom will manage those toward a positive conclusion and implementation”.
“The arrival of biolog-id’s innovative solution on the Brazilian blood bank market will foster the improvement of the traceability and control of processes that remain non-automated yet” underlines Sandra Fujita, Commercial Director at Fujicom. “Based on RFID technology, it will ensure our clients a more efficient management of their product inventory by improving the profitability and the quality of the services provided.”
As previously announced, biolog-id and Fujicom will rely on the expertise of SBS Consultores system - a leading Brazilian software company well established in the transfusion sector – to integrate and implement Biolog Transfusion Solution while providing on-site support.
About biolog-id
:
Biolog-id develops and implements innovative solutions, that digitally transform routine processes into actionable data supporting better operational and strategic decisions for sensitive therapeutic products: blood products (red blood cells, platelets, plasma), chemotherapies, parenteral nutrition.
The information generated by biolog-id solutions is available to Healthcare Professionals at any time, enhancing their processes efficiency, work conditions and ultimately the safety of the therapeutics administered to patients.
Biolog-id’s patented platform is utilized in North America, Europe, Middle East, India, and Asia Pacific. Biolog-id is owned by its founder, managers, and the Xerys Funds. Xerys Invest is a French investment company primarily positioned on trending sectors that include healthcare & Life Sciences, renewable energy/GreenTech and new digital technologies.
Company URL: www.biolog-id.com
About Fujicom:
Fujicom, one of the Fujita Group companies with more than 40 years of presence in the healthcare field, operates throughout Brazil in the commercialization of premium medical-hospital technologies, products, solutions and services.
With its headquarters in Fortaleza and branches in São Paulo and Paraíba, in addition to representatives throughout the country, Fujicom serves more than 500 customers throughout the country, such as blood centers, public and private blood banks, hospitals and clinics.
In Brazil, it has exclusive partnerships with international manufacturers that constantly invest in the development of technologies for their products and share the same goal: Excellence and Innovation.
Company URL: www.fujicom.com.br
View source version on businesswire.com: https://www.businesswire.com/news/home/20210927005515/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Volante Technologies Customers Successfully Navigate Critical Regulatory Deadlines for EU SEPA Instant and Global SWIFT Cross-Border Payments16.12.2025 10:00:00 CET | Press release
PaaS leader ensures seamless migrations and uninterrupted payment operations Volante Technologies, the global leader in Payments as a Service (PaaS), today announced it has successfully upgraded its clients to meet the latest SEPA Instant Payments Regulation (IPR) and SWIFT SRG 2025 mandate, which came into effect October 9th and November 22nd, 2025, respectively. This announcement follows the major FedISO upgrade in July, which shifted trillions of dollars in payments to the new ISO 20022 messaging format. SEPA IPR is a significant European milestone, requiring payments to be made within 10 seconds and at any time of day, throughout the year. Adoption was mandatory and Eurozone banks were compelled to meet strict deadlines, with January 9th, 2025 the deadline for receiving incoming instant payments and October 9th the deadline for sending outgoing instant payments. The latest deadline impacted more than 700 banks across Europe, with non-compliance penalties reaching at least 10% of an
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom